FDA Sends Curis Cancer Drug into Holding Pattern

Curis, a biotech company that develops treatments for cancer, has announced that the U.S. Food and Drug Administration placed a partial clinical hold on its TakeAim lymphoma study while Curis provides the FDA with further data to better understand safety and efficacy questions. This hold comes a week after the FDA placed a hold on another Curis study, putting the company in a dangerous holding pattern.